Hep B Consult: Treat or Monitor
Hep B Consult: US, European, and Asian-Pacific Guideline Recommendations on Whether and How to Treat HBV and HDV

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: March 03, 2023

Expiration: March 01, 2026

About This Tool & Disclaimer

Hep B Consult: US, European, and Asian-Pacific Guideline Recommendations on Whether and How to Treat HBV and HDV

Clinical Care Options, LLC, is grateful to Maria Buti, MD, Paul Y. Kwo, MD, Grace LH Wong, MD, who provided expert guidance, knowledge, and support in the development of this Interactive Decision Support Tool.

Note: The current tool was created in December 2022 and reflects the guidelines available at that time.

The goal of the tool is to educate healthcare professionals on making optimal management choices for monitoring or treating individuals with HBV and HDV infections based on current AASLD, EASL, and APASL practice guidelines in the United States, Europe, or Asia Pacific regions, respectively.

A series of questions allows the user to select individual patient characteristics that are necessary to consider when making management choices. These characteristics include HDV RNA presence, HBeAg status, HBV DNA level, ALT level, liver histology, extrahepatic manifestations, family history of HCC or cirrhosis, bone or renal disease, and other comorbidities.

It should be noted that these are not exclusive characteristics when selecting optimal treatment for patients with chronic hepatitis B or hepatitis delta. Other considerations that are not included in this tool, such as the presence of various comorbidities and any concurrent medications, should also be considered when appropriate for making management decisions.

This tool assumes we have a “standard” patient with chronic hepatitis B or hepatitis delta but with no additional features or specific comorbidities that would affect treatment choice other than those described when entering the patient details. Based on the characteristics entered, the tool will display guideline-based recommendations for that specific patient case.

For additional information on best practices in the management of patients with hepatitis B or hepatitis delta, please see our online module titled, “Insights on the Management of Patients With Chronic Hepatitis B or Hepatitis Delta” authored by Maria Buti, MD; Paul Y. Kwo, MD; and Grace LH Wong, MD.

This program is supported by an educational grant from Gilead Sciences, Inc.

The faculty reported the following financial relationships or relationships to products or devices they have with commercial interests related to the content of this CME activity:

Maria Buti, MD: consultant: Gilead Sciences.

Paul Y. Kwo, MD: consultant/advisor/speaker: Aligos, Antios, Assembly, Enanta, Gilead Sciences, Janssen; researcher: Bristol Myers Squibb, Eiger, Gilead Sciences, Janssen, Target Registries; grant support: Altimmune.

Grace LH Wong, MD: consultant: AbbVie, Gilead Sciences, Janssen.

© 2023 Clinical Care Options, LLC. All rights reserved.

Access to and use of this Interactive Decision Support Tool titled, “Hep B Consult: US, European, and Asian-Pacific Guideline Recommendations on Whether and How to Treat HBV and HDV” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate healthcare professionals on making optimal management choices for monitoring or treating individuals with HBV and HDV infections. The information provided is based on the AASLD, EASL, and APASL guideline recommendations and expert guidance of Maria Buti, MD, Paul Y. Kwo, MD, Grace LH Wong, MD.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Hep B Consult: US, European, and Asian-Pacific Guideline Recommendations on Whether and How to Treat HBV and HDV” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2023 Clinical Care Options, LLC. All rights reserved.

Program Content